

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial No. : 10/525,986

Applicants : Tadashi NAKAJIMA et al.

Filed : February 25, 2005

For : THERAPEUTIC AGENT FOR
GLAUCOMA COMPRISING Rho
KINASE INHIBITOR AND
PROSTAGLANDIN

Art Unit : 1612

Examiner : Sean M. BASQUILL

Docket No. : 05116/HG

Confirm. No.: 5004

Customer No.: 01933

EXPEDITED PROCEDURE
REPLY UNDER 37 CFR 1.116
TECHNOLOGY CENTER 1600

This paper is being submitted
via EFS-Web on

July 10, 2009

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not already paid, authorization to charge the extension fee to Account No. 06-1378. In addition, authorization is hereby given to charge any fees for which payment has not been submitted, or to credit any overpayments, to Account No. 06-1378.

AMENDMENT UNDER 37 CFR 1.116

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAIL STOP AF

S I R :

This is in response to the Office Action mailed January 12, 2009, the term for response to which is extended three months by a PETITION FOR EXTENSION OF TIME filed concomitantly herewith to expire on July 12, 2009. A Notice of Appeal is being filed concomitantly herewith. Please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 5 of this paper.

Remarks begin on page 8 of this paper.